Corporate ActionNov 4, 2026, 04:56 PM
Summit Therapeutics Increases Authorized Shares; Receives $2B from AstraZeneca
AI Summary
Summit Therapeutics Inc. announced the approval and filing of an amendment to its Restated Certificate of Incorporation to increase authorized common stock by 1 billion shares. This follows a significant $2.0 billion strategic equity investment from AstraZeneca. The company also reported its third-quarter financial results, with a GAAP net loss of $208.4 million and $629.8 million in cash and investments. Key clinical developments for ivonescimab continue, with an FDA PDUFA date set for November 14, 2026.
Key Highlights
- Summit Therapeutics Inc. increased authorized shares of common stock by 1,000,000,000 to 2,000,000,000.
- Stockholders approved the amendment to the Restated Certificate of Incorporation with 658,142,561 votes for.
- AstraZeneca completed a $2.0 billion strategic equity investment in Summit Therapeutics.
- Summit Therapeutics reported $629.8 million in cash and investments as of September 30, 2026.
- GAAP net loss for Q3 2026 was $208.4 million, or $(0.26) per share.
- Non-GAAP net loss for Q3 2026 was $160.7 million, or $(0.20) per share.
- FDA PDUFA goal action date for ivonescimab BLA is November 14, 2026.
Price Impact
More from SMMT